## Pymaceuticals Inc.

  Pymaceuticals Inc. provided some data getting from study of performance of Capomulin for analysis. 
In this study, 249 mice identified with SCC tumor growth were treated through a variety of drug regimens. 
Over the course of 45 days, tumor development was observed and measured. 
The purpose of this study was to compare the performance of Pymaceuticals' drug of interest, Capomulin, versus the other treatment regimens.

**Conclusions:**
1) Statistics of the mean, median of the tumor volume for each drug regimen show that provided data is consistent.
2) Capomulin shows the same result as other trusted drugs on the final size of tumor without any exceptions. 
3) Weight of the mouse has a significant effect on the average size of tumor volume. Than heavier mouse than biger volume of tumor.

